Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Delay discounting and reward sensitivity in a 2 × 2 study of bipolar disorder and alcohol dependence.

Mellick W, Tolliver BK, Brenner H, Prisciandaro JJ.

Addiction. 2019 Aug;114(8):1369-1378. doi: 10.1111/add.14625. Epub 2019 May 14.

PMID:
30927381
2.

An evaluation of the impact of co-occurring anxiety and substance use disorder on bipolar disorder illness outcomes in STEP-BD.

Prisciandaro JJ, Mellick W, Mitaro E, Tolliver BK.

J Affect Disord. 2019 Mar 1;246:794-799. doi: 10.1016/j.jad.2018.12.070. Epub 2018 Dec 24.

4.

Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence.

Prisciandaro JJ, Tolliver BK, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF.

Transl Psychiatry. 2017 Jul 4;7(7):e1163. doi: 10.1038/tp.2017.141.

5.
6.

Design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study: A double blind, placebo-controlled trial of omega-3 fatty acid supplementation among adult individuals at risk of suicide.

Marriott BP, Hibbeln JR, Killeen TK, Magruder KM, Holes-Lewis K, Tolliver BK, Turner TH; BRAVO Group.

Contemp Clin Trials. 2016 Mar;47:325-33. doi: 10.1016/j.cct.2016.02.002. Epub 2016 Mar 4.

PMID:
26855120
7.

Assessment and treatment of mood disorders in the context of substance abuse.

Tolliver BK, Anton RF.

Dialogues Clin Neurosci. 2015 Jun;17(2):181-90. Review.

9.

Does alexithymia explain variation in cue-elicited craving reported by methamphetamine-dependent individuals?

Saladin ME, Santa Ana EJ, LaRowe SD, Simpson AN, Tolliver BK, Price KL, McRae-Clark AL, Brady KT.

Am J Addict. 2012 Mar-Apr;21(2):130-5. doi: 10.1111/j.1521-0391.2011.00214.x.

10.

A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report.

Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT.

Bipolar Disord. 2012 Feb;14(1):54-63. doi: 10.1111/j.1399-5618.2011.00973.x.

PMID:
22329472
11.

Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues.

Tolliver BK, Price KL, Baker NL, LaRowe SD, Simpson AN, McRae-Clark AL, Saladin ME, DeSantis SM, Chapman E, Garrett M, Brady KT.

Am J Drug Alcohol Abuse. 2012 May;38(3):251-9. doi: 10.3109/00952990.2011.644000. Epub 2012 Jan 19.

PMID:
22257306
12.

Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.

Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK.

Alcohol Clin Exp Res. 2012 Mar;36(3):490-6. doi: 10.1111/j.1530-0277.2011.01645.x. Epub 2011 Sep 20.

13.

The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.

Price KL, DeSantis SM, Simpson AN, Tolliver BK, McRae-Clark AL, Saladin ME, Baker NL, Wagner MT, Brady KT.

Am J Addict. 2011 Sep-Oct;20(5):447-55. doi: 10.1111/j.1521-0391.2011.00164.x. Epub 2011 Jul 18.

14.

Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial.

Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK.

Psychiatry Res. 2011 Aug 15;188(3):361-5. doi: 10.1016/j.psychres.2011.04.030. Epub 2011 Jun 8.

15.

Cognitive enhancers in the treatment of substance use disorders: clinical evidence.

Brady KT, Gray KM, Tolliver BK.

Pharmacol Biochem Behav. 2011 Aug;99(2):285-94. doi: 10.1016/j.pbb.2011.04.017. Epub 2011 Apr 29. Review.

16.

Predictors of clinical trial dropout in individuals with co-occurring bipolar disorder and alcohol dependence.

Prisciandaro JJ, Rembold J, Brown DG, Brady KT, Tolliver BK.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):493-6. doi: 10.1016/j.drugalcdep.2011.03.029. Epub 2011 May 6.

17.

Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders.

Gao K, Chan PK, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Bilali S, Brady KT, Findling RL, Calabrese JR.

Am J Addict. 2010 Sep-Oct;19(5):440-9. doi: 10.1111/j.1521-0391.2010.00060.x.

18.

Extinction of drug cue reactivity in methamphetamine-dependent individuals.

Price KL, Saladin ME, Baker NL, Tolliver BK, DeSantis SM, McRae-Clark AL, Brady KT.

Behav Res Ther. 2010 Sep;48(9):860-5. doi: 10.1016/j.brat.2010.05.010. Epub 2010 May 19.

19.

Determinants of cue-elicited craving and physiologic reactivity in methamphetamine-dependent subjects in the laboratory.

Tolliver BK, McRae-Clark AL, Saladin M, Price KL, Simpson AN, DeSantis SM, Baker NL, Brady KT.

Am J Drug Alcohol Abuse. 2010 Mar;36(2):106-13. doi: 10.3109/00952991003686402.

PMID:
20337507
20.

Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment.

Gao K, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KL, Findling RL, Calabrese JR.

J Clin Psychiatry. 2009 Jul;70(7):1032-40.

21.

Biologic Commonalities between Mental Illness and Addiction.

Hartwell KJ, Tolliver BK, Brady KT.

Prim psychiatry. 2009 Aug 1;16(8):33-39.

22.

Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series.

Tolliver BK, McRae AL, Verduin ML, Anderson SJ, Brady KT.

J Clin Psychopharmacol. 2008 Aug;28(4):464-7. doi: 10.1097/JCP.0b013e31817efb99. No abstract available.

PMID:
18626281
23.

Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials.

Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Elhaj O, Bilali S, Brady KT, Findling RL, Calabrese JR.

J Clin Psychiatry. 2008 Jul;69(7):1057-63.

24.

Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder.

Gao K, Tolliver BK, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady KT, Shim SS, Findling RL, Calabrese JR.

J Affect Disord. 2008 Sep;110(1-2):167-73. doi: 10.1016/j.jad.2007.12.229. Epub 2008 Jan 29.

25.

Treatment of patients comorbid for addiction and other psychiatric disorders.

Brady KT, Verduin ML, Tolliver BK.

Curr Psychiatry Rep. 2007 Oct;9(5):374-80. Review.

PMID:
17915076
26.

Alcohol use and anxiety: diagnostic and management issues.

Brady KT, Tolliver BK, Verduin ML.

Am J Psychiatry. 2007 Feb;164(2):217-21; quiz 372. No abstract available.

PMID:
17267782
27.

Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization.

Reid MS, Ho LB, Hsu K, Fox L, Tolliver BK, Adams JU, Franco A, Berger SP.

Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):37-54.

PMID:
11812506
28.
29.
30.

Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.

Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K Jr, Berger SP.

J Pharmacol Exp Ther. 1999 Apr;289(1):110-22.

PMID:
10086994
31.
32.

Partial reversal of stress-induced behavioral sensitization to amphetamine following metyrapone treatment.

Reid MS, Ho LB, Tolliver BK, Wolkowitz OM, Berger SP.

Brain Res. 1998 Feb 2;783(1):133-42.

PMID:
9479062
33.
34.

Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants.

Tolliver BK, Ho LB, Reid MS, Berger SP.

J Pharmacol Exp Ther. 1996 Jul;278(1):411-20.

PMID:
8764377
35.

Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization.

Reid MS, Hsu K, Tolliver BK, Crawford CA, Berger SP.

J Pharmacol Exp Ther. 1996 Mar;276(3):1244-56.

PMID:
8786557
36.

Locomotor stimulant effects of cocaine and novel cocaine analogs in DBA/2J and C57BL/6J inbred mice.

Tolliver BK, Carney JM.

Pharmacol Biochem Behav. 1995 Feb;50(2):163-9.

PMID:
7740054
37.

Genetic analysis of sensitization and tolerance to cocaine.

Tolliver BK, Belknap JK, Woods WE, Carney JM.

J Pharmacol Exp Ther. 1994 Sep;270(3):1230-8.

PMID:
7932176
38.

Comparison of cocaine and GBR 12935: effects on locomotor activity and stereotypy in two inbred mouse strains.

Tolliver BK, Carney JM.

Pharmacol Biochem Behav. 1994 Jul;48(3):733-9.

PMID:
7938129
39.

Sensitization to stereotypy in DBA/2J but not C57BL/6J mice with repeated cocaine.

Tolliver BK, Carney JM.

Pharmacol Biochem Behav. 1994 May;48(1):169-73.

PMID:
8029287

Supplemental Content

Loading ...
Support Center